Finnish biology inventors selected as finalists for the European Inventor Award 2024
The husband-and-wife team, Sirpa and Markku Jalkanen, developed a clinical treatment to activate the immune system in fighting cancer cells. They were selected from over 550 candidates as finalists in the ‘SMEs’ category of the European Inventor Award 2024, competing against a French team and a Polish one.
Igniting the immune system to target cancer
Bexmarilimab, the drug developed by this husband-and-wife team, better equips the immune system to fight cancer cells, making it a form of immunotherapy, which is an increasingly important area in cancer treatment. This new treatment aims to overcome resistance to current therapies and improve outcomesOpen link in a new tab. So, when used with standard cancer treatments, Bexmarilimab could enhance their effectiveness and extend the benefits of immunotherapy to more patients with different types of cancer.
Making cancer research a family affair
After meeting just after high school, Sirpa and Markku Jalkanen pursued the same career path, starting in Finland and developing part of their research career in the US. Sirpa, unable to practice clinically in this country, where Markku was pursuing a post doctorate at Stanford, became a leading researcher in lymphocyte migration in the human immune defence system.
Markku pioneered Finnish biotech development while being the first Director of Turku Bioscience Centre within the BioCity community in Turku. Together, they founded Faron Pharmaceuticals in 2007, with their children also having roles in the business and development aspect of the company.
The winners will be announced on 9 July in Malta
The EPO will announce the winners of the different categories during a ceremony livestreamed here from Malta on 9 July 2024. In addition, the EPO will reveal the Popular Prize winner, chosen by online public vote. Voting will remain open until the day of the ceremony.Open link in a new tab
Media contacts
European Patent Office
Luis Berenguer Giménez
Principal Director Communication / EPO spokesperson
EPO press desk
press@epo.org
Tel.: +49 89 2399-1833
About the European Inventor Award
The European Inventor Award is one of Europe's most prestigious innovation prizes. Launched by the EPO in 2006, the award honours individuals and teams, who have come up with solutions to some of the biggest challenges of our time. The European Inventor Award jury consists of inventors who are all former finalists. All inventors must have been granted a European patent for their invention.
To judge proposals, the independent panel draws on their wealth of technical, business, and intellectual property expertise. In 2024, the jury is chaired by Wolfgang M. Heckl.
About the EPO
With 6,300 staff members, the European Patent Office (EPO) is one of the largest public service institutions in Europe.Open link in a new tab Headquartered in Munich with offices in Berlin, Brussels, The Hague and Vienna, the EPO was founded with the aim of strengthening co-operation on patents in Europe. Through the EPO's centralised patent granting procedure, inventors are able to obtain high-quality patent protection in up to 45 countries, covering a market of some 700 million people. The EPO is also the world's leading authority in patent information and patent searching.